humacao_exterior

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

pharmafile | October 13, 2017 | News story | Sales and Marketing |  BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical 

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for inclusion in the Cancer Drugs Fund (CDF) for the treatment of squamous cell carcinoma of the head and neck which has metastasized in patients who have not responded to chemotherapy within six months.

On initial review of the drug, NICE found that evidence on Opdivo’s efficacy in head and neck cancer proved inconclusive and could not approve it for use on the NHS. Following this decision, NICE invited BMS to instead submit a CDF proposal for the drug.

The agreement which has now been reached by the two parties means that Opdivo will now be made available via a commercial access agreement at a lower cost than its £1,037 list price per 100mg vial. While available on the CDF, data will continue to be gathered on its use in order to build its efficacy profile and potentially address NICE’s initial concerns.

Advertisement

“Nivolumab is an innovative drug that continues to draw attention, but its clinical evidence for some types of cancer can be uncertain,” commented Professor Carole Longson, Director of the Centre for Health Technology Evaluation at NICE. “I am pleased the company has worked with us and NHS England to develop a managed access agreement and that we have found a way to provide for patients despite these uncertainties.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

NICE recommends allergy immunotherapy tablets for younger children

NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

The Gateway to Local Adoption Series

Latest content